Latest Biotech News

Verily integrated Nvidia’s GPU‑accelerated libraries and Blackwell/Hopper GPUs into its Pre precision health research platform to speed genomic and multiomics analyses for researchers, including...

Co‑Diagnostics priced a $7 million direct offering to institutional investors to fund working capital and corporate purposes, and the company also established a joint venture with Arabian Eagle...

Novartis announced an agreement to acquire Avidity Biosciences for roughly $12 billion, adding three late-stage antibody‑oligonucleotide conjugate (AOC) programs aimed at neuromuscular diseases....

Intellia Therapeutics paused enrollment and dosing in two late‑stage trials of its CRISPR candidate nex‑z after a study volunteer was hospitalized with severe liver injury. The company moved...

Takeda Pharmaceutical agreed to codevelop and commercialize up to three immuno‑oncology (I‑O) and antibody‑drug conjugate (ADC) candidates from Innovent Biologics in a deal valued at up to $11.4...

BridgeBio reported positive interim Phase 3 data for BBP‑418 in limb‑girdle muscular dystrophy type 2I/R9, meeting prespecified thresholds and prompting the company to seek discussions with the...

Zenas Biopharma reported that obexelimab, a bifunctional monoclonal antibody, produced a 95% reduction in new gadolinium‑enhancing T1 brain lesions at 12 weeks in the Phase 2 MoonStone study in...

GSK licensed EMP‑012, a Phase 1 siRNA candidate from Empirico targeting inflammatory pathways in chronic obstructive pulmonary disease (COPD), paying an $85 million upfront fee and reserving up to...

Health Canada granted a Notice of Compliance with Conditions for LEQEMBI (lecanemab), authorizing the anti‑amyloid monoclonal antibody for adults with mild cognitive impairment or mild dementia...

Guardant Health struck a strategic collaboration with Zephyr AI to combine Guardant’s multimodal molecular datasets from its genomic testing platform with Zephyr’s AI and machine learning...

Hemab Therapeutics closed a $157 million financing to advance a portfolio targeting ‘underserved’ coagulation disorders, including a pivotal program for Glanzmann thrombasthenia and an early...

Ena Respiratory closed an AU$34 million (US$22.4 million) Series B to advance INNA‑051, a nasal spray candidate for symptomatic viral respiratory infections, into Phase II. Investors include the...

Novartis agreed to acquire Avidity Biosciences for roughly $12 billion, taking ownership of three late-stage antibody-oligonucleotide conjugate (AOC) programs targeting neuromuscular diseases. The...

Intellia Therapeutics paused enrollment and dosing in two Phase 3 trials of its in vivo CRISPR candidate after a study volunteer was hospitalized with severe liver toxicity. The company said it is...

GSK struck an exclusive license with Empirico for an inhaled siRNA candidate targeting non‑type 2 inflammatory COPD, paying $85 million upfront and up to hundreds of millions in milestones. The...

Zenas Biopharma reported a midstage (MoonStone) trial result showing a ~95% reduction in new Gd‑enhancing brain lesions at Weeks 8–12 with obexelimab versus placebo in relapsing multiple...

BridgeBio posted an interim Phase 3 readout for BBP‑418 in LGMD2I/R9 that the company described as a potential 'home run,' prompting plans to meet the FDA to discuss an NDA submission. The interim...

Zag Bio launched with an $80 million Series A to develop thymus‑targeted bifunctional antibodies designed to induce regulatory T cells (Tregs) for autoimmune disease. The round included strategic...

Danaher subsidiary Cepheid’s Xpert MTB/XDR assay received World Health Organization prequalification for genotypic detection of resistance to multiple first‑ and second‑line tuberculosis drugs....

Revvity reported that its diagnostics business grew in Q3 driven by newborn screening and immunodiagnostics, with diagnostics revenue rising 3% year over year. Company executives cited new...